Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech Inc., a leader in immunotherapy for oncology, will present two studies at the 2024 ASCO Annual Meeting, highlighting promising results of their drug pelareorep in combination with other treatments for pancreatic and breast cancer. The presentations will include a Phase 1/2 study on metastatic pancreatic ductal adenocarcinoma and research on blood TIL expansion in various cancers. The company is advancing towards pivotal trials with FDA Fast Track designation for pelareorep in metastatic breast and pancreatic cancers.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
